Barthelemy and collaborators [13, 14] identified peptides in the CSF of AD where they are abundant but also in the CSF of PSP, Lewy body dementia (LBD) and control groups where tau concentrations are very low. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.